At a post-Halloween public hearing this week (Tuesday and Wednesday), the FDA will be soliciting public commentary about several direct-to-consumer (DTC) advertising techniques employed by pharmaceutical marketers. This process is scary to some pharma marketers who fear a new round of DTC regulations from FDA. This trick, however, may have been forestalled by PhRMA's treat: its Guiding Principles for DTC, which were revealed in August.

I will be attending this meeting and will report here on what, if anything, I learn.

In the meantime, read today's Pharma Marketing Blog for preliminary results from the ongoing survey of PMN subscribers about the issues that the FDA will be looking at.

Read more about this in today's post to Pharma Marketing Blog. (Includes some interesting comments from respondents in their own words)